Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma

Summary

This is a Phase I dose-escalation study to evaluate the safety, tolerability and preliminary efficacy of an autologous BCMA-targeting RNA-engineered CAR T-cell therapy in patients with Relapsed/Refractory Multiple Myeloma. The cell product is referred to as Descartes-15

Timeline

Start

2024-06-19

Primary completion

2025-04-14

Completion

2025-11-13

Outcome

Outcome not reported

Stopped (Enrollment): “Phase 1 enrollment completed. Further clinical development terminated”

Drugs

Indications